IDH1 and neoplasm: Finally, 83% (15/18) of the plasma ctDNA-negative samples obtained from the six patients with IDH1-mutant tumors (NGS) occurred in patients with treated disease or without evidence of tumor progression (Table 1 and Supplementary Table S2).